Katerina Vervita

Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score

Nathan I. Cherny, Elisabeth G.E. de Vries, Urania Dafni et al. · Journal of Clinical Oncology · 2019 · 120 citations · Full text

Pharmacy, Oncology, Comparative Effectiveness Research +14

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Ross A. Soo, Ji‐Youn Han, Urania Dafni et al. · Annals of Oncology · 2021 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Solange Peters, Jean-Louis Pujol, Urania Dafni et al. · Annals of Oncology · 2021 · 114 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database

Isabelle Opitz, Andrea Billè, Urania Dafni et al. · Journal of Thoracic Oncology · 2023 · 16 citations · Full text

Medicine, Oncology, Surgery +13